IRVINE, CA--(Marketwire - October 01, 2009) - MiCardia® (MiCardia® Corporation,
Irvine, California) today announced that The United States Patent Office
granted patent number US7,594,887 B2, "Shape Memory Devices and Methods for
Reshaping Heart Anatomy," on September 29th, 2009.
MiCardia Chief Technical Officer, Founder and co-inventor, Mr. Samuel
Shaolian describes the patent as allowing for systems, methods and devices
capable of reshaping the anatomy of the heart by implanting shape memory
elements. Commenting on this patent issuance Mr. Shaolian said, "This
patent foresees ways to manage disease caused by induced dilation of the
ventricles of the heart and the associated reduced contractility of the
heart muscle which leads ultimately to heart failure. MiCardia's technology
allows adjustable implants in the heart to be tuned to positively affect
stroke volume and cardiac output. If we can remodel the shape of the
ventricles so that blood can be pumped out more efficiently, it may be
possible to halt the progression of heart failure or even reverse it. The
most recent patent is part of an expanding suite of intellectual property
focused on shape memory and magnetically activated implantable technologies
that we have developed since our founding. These devices represent a new
generation of therapeutic implants that are truly dynamic and allow the
physician to make adjustments to the heart's shape minimally invasively
long after the initial procedure. By extending the therapeutic window of
implantable heart devices we believe we can positively affect the long-term
outcomes for patients."
Commenting on the most recent patent issuance, Mr. Paul Molloy, Chief
Executive Officer at MiCardia said "MiCardia is dedicated to treating
structural heart disease and the consequent incidence of heart failure
which affects more than 15 million people in the US and Europe today.
MiCardia's first Dynaplasty®
devices will be available in Europe in early 2010 and provide ground
breaking solutions for the treatment of recurrent mitral and tricuspid
valve regurgitation. These are key components of the heart failure
equation. MiCardia's ninth patent, combined with our existing portfolio of
eight issued and forty pending patents, represent a tremendous asset for
the company on which new therapies can be built."
MiCardia® is a privately held company, founded in 2004 and is developing
a completely unique treatment technology that will allow adjustment of
cardiac anatomy both intra-operatively and post-operatively. Surgical,
percutaneous and entirely non-invasive activation platforms are in advanced
The MiCardia® Dynamic Annuloplasty System is not currently available in
the USA. Clinical evaluation is in progress. Not available for sale.
MiCardia®, Dynaplasty and Dynamic Annuloplasty System are registered
trademarks of MiCardia® Corporation. All rights reserved.